Results 41 to 50 of about 108,133 (341)

Combination GLP-1 and Insulin Treatment Fails to Alter Myocardial Fuel Selection Versus Insulin Alone in Type 2 Diabetes [PDF]

, 2018
Context Glucagon-like peptide-1 (GLP-1) and the clinically available GLP-1 agonists have been shown to exert effects on the heart. It is unclear whether these effects occur at clinically used doses in vivo in humans, possibly contributing to CVD risk ...
Considine, Robert V., Goodwill, Adam, Green, Mark A., Hamilton, LaTonya, Hutchins, Gary D., Mather, Kieren J., Mathias, Carla, Patel, Niral A., Territo, Wendy, Tune, Johnathan D.   +9 more
core   +1 more source

Genetic aspects of type 1 glucagon peptide agonists clinical efficacy: A review

Терапевтический архив, 2023
A review of publications devoted to the analysis of genetic polymorphisms of the gene encoding the glucagon-like peptide type 1 receptor and some other genes directly and indirectly involved in the implementation of its physiological action is presented.
Evgenya L. Golovina, Ivan R. Grishkevich, Olga E. Vaizova, Iuliia G. Samoilova, Darja V. Podchinenova, Mariia V. Matveeva, Dmitry A. Kudlay   +6 more
doaj   +1 more source

The effect of the GLP-1 analogue Exenatide on functional connectivity within an NTS-based network in women with and without obesity. [PDF]

, 2017
ObjectiveThe differential effect of GLP-1 agonist Exenatide on functional connectivity of the nucleus tractus solitaries (NTS), a key region associated with homeostasis, and on appetite-related behaviours was investigated in women with normal weight ...
Connolly, L, Coveleskie, K, Gupta, A, Kilpatrick, LA, Labus, JS, Mayer, EA, Sanmiguel, C, Stains, J   +7 more
core   +3 more sources

A Health Technology Assessment Based on Chinese Guidelines: Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Type 2 Diabetes Complicated with Cardiovascular Disease

Therapeutics and Clinical Risk Management, 2022
Zeyu Xie, Jinjian Li, Sensen Yang, Weishang Deng, Jisheng Chen Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, People’s Republic of ChinaCorrespondence: Jisheng Chen, Key Specialty of ...
Xie Z, Li J, Yang S, Deng W, Chen J
doaj  

Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia

Clinical Medicine Insights: Endocrinology and Diabetes, 2021
A relatively recent addition to the arsenal of antidiabetic drugs used for the treatment of type 2 diabetes mellitus (T2DM) has been the “incretin mimetics,” a group of drugs that work on the glucagon-like peptide-1 (GLP-1) receptor and enhance insulin ...
Daria Ja’arah, Mazhar Salim Al Zoubi, Gamal Abdelhady, Firas Rabi, Murtaza M Tambuwala   +4 more
doaj   +1 more source

The effects of species ortholog and SNP variation on receptors for free fatty acids [PDF]

, 2013
Although it is widely assumed that species orthologs of hormone responsive G protein-coupled receptors will be activated by the same endogenously produced ligand(s), variation in potency, particularly in cases where more than one receptor responds to the
1000 Genomes Project Consortium, Bellahcene, Bergman, Bjursell, Blad, Brian D. Hudson, Briscoe, Brown, Burant, Christiansen, Christiansen, Christiansen, Christiansen, Cummings, Edfalk, Fredriksson, Galindo, Ge, Graeme Milligan, Hamid, Hannah Murdoch, Hirasawa, Hong, Hudson, Hudson, Hudson, Hudson, Humphries, Ichimura, Insel, Itoh, Kaku, Kalis, Kebede, Kebede, Kimura, Lan, Latour, Le Poul, Leonard, Liaw, Lin, Luo, Maslowski, Milligan, Milligan, Moore, Negoro, Ogawa, Oh, Ryan, Sawzdargo, Schmidt, Shimpukade, Sina, Smith, Smith, Steneberg, Stoddart, Stoddart, Strasser, Sum, Tan, Taneera, Tolhurst, Vettor, Watson, Wolever, Xiong, Xiong, Yashiro, Zaibi, Zhou   +72 more
core   +1 more source

Clinical pharmacology of glucagon-like peptide-1 receptor agonists

Hormones, 2018
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are an important asset in the armamentarium for the treatment of type 2 diabetes mellitus (type 2 DM). Incretin failure is a critical etiopathogenetic feature of type 2 DM, which, if reversed, results in improved glycaemic control.
Sfairopoulos, D., Liatis, S., Tigas, S., Liberopoulos, E.   +3 more
openaire   +3 more sources

Elective peri‐operative management of adults taking glucagon‐like peptide‐1 receptor agonists, glucose‐dependent insulinotropic peptide agonists and sodium‐glucose cotransporter‐2 inhibitors: a multidisciplinary consensus statement

Anaesthesia
Glucagon‐like peptide‐1 receptor agonists, dual glucose‐dependent insulinotropic peptide receptor agonists and sodium‐glucose cotransporter‐2 inhibitors are used increasingly in patients receiving peri‐operative care.
K. El-Boghdadly, J. Dhesi, Philippa Fabb, N. Levy, D. N. Lobo, A. McKechnie, Omar Mustafa, P. Newland-Jones, Anil Patel, D. Pournaras, Ken Clare, K. Dhatariya   +11 more
semanticscholar   +1 more source

Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER

Circulation, 2021
Supplemental Digital Content is available in the text. Background: We assessed the effect of once-weekly semaglutide and once-daily liraglutide on kidney outcomes in type 2 diabetes.
Ahmed M. Shaman, Stephen C. Bain, G. Bakris, J. Buse, Thomas Idorn, K. Mahaffey, J. Mann, M. Nauck, S. Rasmussen, P. Rossing, B. Wolthers, B. Zinman, V. Perkovic   +12 more
semanticscholar   +1 more source

Differential effects of glucagon-like peptide-1 receptor agonists on heart rate [PDF]

, 2017
While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are known to increase heart rate (HR), it is insufficiently recognized that the extent varies greatly between the various agonists and is affected by the assessment methods employed.
A Asmar, A Asmar, A Ceriello, A Gill, A Jorsal, A Jorsal, A Plamboeck, AA Voors, AG Bertoni, Anne Lehmann, B Darpo, B Darpo, B Mendis, BM Scirica, C Perret-Guillaume, C Pyke, Christine Roy-Duval, David Owens, Denis Raccah, DJ Drucker, Francesca Lawson, GS Hillis, GS Hillis, H Linnebjerg, J Can van, J Skov, J Tillner, JA Lovshin, JJ Meier, JJ Meier, JR Ussher, K Swedberg, KB Margulies, KB Margulies, KC Ferdinand, KJ Griffioen, L Blonde, L Ryden, Lawrence Blonde, LE Robinson, LG Trahair, M Kim, M Komajda, M Lorenz, MA Nauck, MA Pfeffer, Martin Lorenz, MT Cooney, P Kumarathurai, P Sager, R Simo, Riccardo Perfetti, RR Holman, SE Inzucchi, SP Marso, T Vilsboll, X Zhou, Y Nakatani   +57 more
core   +1 more source